As the threat of superbugs rise amid growing resistance to antibiotics, Clostridium dificile infections are becoming more common in healthcare settings across the U.S. To combat this serious infection, two small biotechs have unveiled positive preclinical data backing potential new therapies.
An experimental vaccine for Clostridium difficile provided protection in 100% of mice and monkeys that received it. With antibiotic resistance on the rise, the vaccine could be a valuable preventive measure against the infection, which kills about 30,000 Americans every year.
Quidel won a coveted 510(k) clearance from the FDA for a new hand-held molecular diagnostic test to detect DNA for Clostridium difficile bacteria.
Clostridium difficile, or C. difficile, is a nasty bit of business. It can be the scourge of hospitals, striking patients when antibiotics kill all the "good bugs" that dwell in the gut--like the
Clostridium difficile: Yes, it is just as nasty as it sounds. C. difficile is a "superbug" that is the scourge of hospitals. It strikes when antibiotics kill all the "good bugs" that dwell in your